Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 219

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

Open access
Johnston, Patrick B., Inwards, David J., Colgan, Joseph P., Laplant, Betsy R., Kabat, Brian F., Habermann, Thomas M., Micallef, Ivana N., Porrata, Luis F., Ansell, Stephen M., Reeder, Craig B., Roy, Vivek, Witzig, Thomas E. · 2010 · American Journal of Hematology

Abstract

Everolimus is an oral antineoplastic agent that targets the raptor mammalian target of rapamycin (mTORC1). The phosphatidylinositol 3‐kinase/mTOR signal transduction pathway has been demonstrated to be activated in tumor samples from patients with Hodgkin lymphoma (HL). The goal of this trial was to learn the antitumor activity and toxicity of everolimus in patients with relapsed/refractory HL. Patients were eligible if they had measurable disease, a platelet count >75,000, and an absolute neutrophil count >1,000. Patients received everolimus 10 mg PO daily. Dose reductions were allowed. Response was assessed after two and six cycles and then every three cycles until progression. Patients could remain on drug until progression or toxicity. Nineteen patients were enrolled. Median age was 37 years (range, 27–68). Patients had received a median of six prior therapies (range, 3–14) and 84% had undergone prior autologous stem cell transplant. The ORR was 47% (95% CI: 24–71%) with eight patients achieving a PR and one patient achieving a CR. The median TTP was 7.2 months. Four responders remained progression free at 12 months. Patients received a median of seven cycles of therapy. Of the 19 patients, one remains on therapy at 36 months; the others went off study because of progressive disease (16), toxicity (1), and death from infection (1). Four patients experienced a Grade 3 or higher pulmonary toxicity. Everolimus has single‐agent activity in relapsed/refractory HL and provides proof‐of‐concept that targeting the mTOR pathway in HL is clinically relevant. Am. J. Hematol., 2010. © 2010 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ajh.21664

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 219

Metadata

Authors
Johnston, P. B., Inwards, D. J., Colgan, J. P., Laplant, B. R., Kabat, B. F., Habermann, T. M., Micallef, I. N., Porrata, L. F., Ansell, S. M., Reeder, C. B., Roy, V., & Witzig, T. E.
Venue
American Journal of Hematology
Publisher
Wiley
Published
2010-04-21
Volume
85
Issue
5
Pages
320-324
ISSN
  • 0361-8609 (ISSN-L)
  • 1096-8652
OpenAlex
W2166258988
Cited by
219
References
4
FWCI
15.77
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. https://app.cochat.ai/papers/10.1002/ajh.21664
The paper
Johnston, P. B., Inwards, D. J., Colgan, J. P., Laplant, B. R., Kabat, B. F., Habermann, T. M., Micallef, I. N., Porrata, L. F., Ansell, S. M., Reeder, C. B., Roy, V., & Witzig, T. E. (2010). A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. American Journal of Hematology. https://doi.org/10.1002/ajh.21664

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.